Technical Analysis for LQDA - Liquidia Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | -0.39% | |
Stochastic Buy Signal | Bullish | -0.39% | |
Lower Bollinger Band Walk | Weakness | -0.39% | |
Multiple of Ten Bullish | Other | -0.39% | |
Outside Day | Range Expansion | -0.39% | |
Lower Bollinger Band Touch | Weakness | -0.39% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 21 hours ago |
Up 1% | about 21 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Down 1% | about 22 hours ago |
Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/13/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Opioids Clinical Trial Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 6.69 |
Average Volume | 885,674 |
200-Day Moving Average | 12.32 |
50-Day Moving Average | 10.55 |
20-Day Moving Average | 10.60 |
10-Day Moving Average | 10.35 |
Average True Range | 0.42 |
RSI (14) | 41.18 |
ADX | 20.13 |
+DI | 19.52 |
-DI | 21.28 |
Chandelier Exit (Long, 3 ATRs) | 10.21 |
Chandelier Exit (Short, 3 ATRs) | 10.98 |
Upper Bollinger Bands | 11.43 |
Lower Bollinger Band | 9.76 |
Percent B (%b) | 0.21 |
BandWidth | 15.74 |
MACD Line | -0.20 |
MACD Signal Line | -0.10 |
MACD Histogram | -0.0937 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.65 | ||||
Resistance 3 (R3) | 10.65 | 10.48 | 10.56 | ||
Resistance 2 (R2) | 10.48 | 10.35 | 10.48 | 10.53 | |
Resistance 1 (R1) | 10.30 | 10.26 | 10.22 | 10.30 | 10.50 |
Pivot Point | 10.13 | 10.13 | 10.09 | 10.13 | 10.13 |
Support 1 (S1) | 9.95 | 10.00 | 9.87 | 9.95 | 9.74 |
Support 2 (S2) | 9.78 | 9.91 | 9.78 | 9.71 | |
Support 3 (S3) | 9.60 | 9.78 | 9.68 | ||
Support 4 (S4) | 9.60 |